Search alternatives:
- Subject ("T cell engagers") »
Loading…
An Innovative Approach to Optimize First-In-Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T-Cell Engagers: Experience from A Solid Tumor Bispecific T-Cell Engager
Zhou, Di, Kischel, Roman, Stienen, Sabine, Townsley, Danielle, Sternjak, Alexander, Lutteropp, Michael, Bailis, Julie, Friedrich, Matthias, Rattel, Benno, Mehta, Khamir, Upreti, Vijay V
Published in Clinical pharmacology and therapeutics (01.01.2025)
Published in Clinical pharmacology and therapeutics (01.01.2025)
Get more information
Journal Article
Loading…
A Mechanistic Physiologically-Based Pharmacokinetic Platform Model to Guide Adult and Pediatric Intravenous and Subcutaneous Dosing for Bispecific T Cell Engagers
Zhang, Xinwen, Lumen, Annie, Wong, Hansen, Connarn, Jamie, Dutta, Sandeep, Upreti, Vijay V
Published in Clinical pharmacology and therapeutics (01.03.2024)
Published in Clinical pharmacology and therapeutics (01.03.2024)
Get more information
Journal Article
Loading…
Celmod-Dexamethasone Combination Overcomes Primary Resistance to T Cell Engagers Caused By High Tumor Burden in a Human CRBN+ Preclinical Model of Multiple Myeloma
Meermeier, Erin W, Sharik, Meaghen, Du, Megan, Stein, Caleb K, Zhu, Yuan Xiao, Shi, Chang-Xin, Shotts, Yuliza, Bergsagel, Leif, Chesi, Marta
Published in Blood (05.11.2024)
Published in Blood (05.11.2024)
Get full text
Journal Article
Loading…
Dose intra‐subject escalation to an event (DIETE): A new method for phase 1 dose‐finding utilizing systematic intra‐subject dose escalation with application to T‐cell engagers
Xu, Chenjia, Zhuo, Bin, Rasmussen, Hans Erik
Published in Pharmaceutical statistics : the journal of the pharmaceutical industry (01.11.2021)
Published in Pharmaceutical statistics : the journal of the pharmaceutical industry (01.11.2021)
Get full text
Journal Article
Loading…
Unraveling the Mechanism of Action of Bispecific T-Cell Engagers in B-Cell Acute Lymphoblastic Leukemia Using Advanced Single-Cell Multiomics
Gurevich Shapiro, Anna, Winter, Eitan, Moshe, Yakir, Katzenelenbogen, Yonatan, Jaitin, Diego, Zada, Mor, Barboy, Oren, Yofe, Ido, Chalan, Paulina, Truong Phan, San, Giladi, Amir, Shapiro, Michael, Robinson, Renana, Kugler, Eitan, Wolach, Ofir, Avivi Mazza, Irit, Amit, Ido
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Loading…
PROCESS DEVELOPMENT FOR NURSING EDUCATION FOR THE DELIVERY OF BISPECIFIC T-CELL ENGAGERS IN THE COMMUNITY OUTPATIENT ONCOLOGY SETTING
Patterson, Sharifa, Murphy, Kathleen, Steinfeld, Martie, Todd, Ashley, Traughber, Chelsea
Published in Oncology nursing forum (01.03.2024)
Get full text
Published in Oncology nursing forum (01.03.2024)
Journal Article
Loading…
Bispecific antibody targets and therapies in multiple myeloma
Rees, Matthew, Abdallah, Nadine, Yohannan, Binoy, Gonsalves, Wilson I.
Published in Frontiers in immunology (10.10.2024)
Published in Frontiers in immunology (10.10.2024)
Get full text
Journal Article
Loading…
Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T-Cell Engager, in Prostate Cancer Patients
Kuipers-Connarn, Jamie N, Pourzanjani, Arya, Bose, Maitreyee, Modi, Saurabh, Stieglmaier, Julia, Murphy, Alexis, Mehta, Khamir, Upreti, Vijay V
Published in Journal of clinical pharmacology (05.08.2025)
Published in Journal of clinical pharmacology (05.08.2025)
Get more information
Journal Article
Loading…
Time Limited Exposure to a ROR1 Targeting Bispecific T Cell Engager (NVG-111) Leads to Durable Responses in Subjects with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
Townsend, William, Leong, Sarah, Shah, Mittal, Batten, Toby, Tucker, David, Pottinger, Bryson, Paneesha, Shankaranarayana, El-Sharkawi, Dima, Eyre, Toby A., Lam, Ho Pui Jeff, Zheng, Jiexin, Cook, Sarah, Granger, David, Ahern, David, O'Donovan, Kieran, Nathwani, Amit C., Jasani, Parag
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Loading…
First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)
Townsend, William, Leong, Sarah, Tucker, David, Pottinger, Bryson, Paneesha, Shankara, El-Sharkawi, Dima, Eyre, Toby A., Batten, Toby, Shah, Mittal, Cook, Sarah, Granger, David, O'Donovan, Kieran, Nathwani, Amit C., Jasani, Parag
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Loading…
Immunotherapy of Acute Myeloid Leukemia Enabled By Targeting of Pan-Cancer Molecular Patterns with a Novel Trispecific T Cell Engager
Varkey, Ashley, Bariana, Manpreet, Cassella, Elena, Anuncio, Shaina, Batistick, Mark, Sequeira, Sonia, Ahmed, Mahiuddin, Zakrzewski, Johannes
Published in Blood (05.11.2024)
Published in Blood (05.11.2024)
Get full text
Journal Article
Loading…
Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial
Gaballa, Sameh, Nair, Ranjit, Jacobs, Ryan W, Devata, Sumana, Cho, Seok-Goo, Stevens, Don A., Yoon, Dok Hyun, Shah, Nirav N., Brennan, Denise, Law, Jason, Chen, Robert, Sermer, David, Lesley, Robin, Buelow, Ben, Forcina, Alessandra, Hou, Jing-Zhou
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Loading…
Phase 2 study of tarlatamab, a DLL3-targeting, half life-extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC)
Ramalingam, Suresh S., Ahn, Myung-Ju, Akamatsu, Hiroaki, Blackhall, Fiona Helen, Borghaei, Hossein, Hummel, Horst-Dieter, Johnson, Melissa Lynne, Reck, Martin, Zhang, Yiran, Jandial, Danielle, Cheng, Sunfa, Paz-Ares, Luis G.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Loading…
A phase I study to evaluate the T-cell engager AMV564 alone and in combination with pembrolizumab in subjects with advanced solid tumors
Starodub, Alexander, Piha-Paul, Sarina Anne, Karim, Raghad, Ruegg, Curtis, Smith, Victoria, Chun, Patrick Youngwhan
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Loading…
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy
Penny, Hweixian Leong, Hainline, Kelly, Theoharis, Nathaniel, Wu, Bin, Brandl, Christian, Webhofer, Christian, McComb, Mason, Wittemer-Rump, Sabine, Koca, Gökben, Stienen, Sabine, Bargou, Ralf C., Hummel, Horst-Dieter, Loidl, Wolfgang, Grüllich, Carsten, Eggert, Tobias, Tran, Ben, Mytych, Daniel T.
Published in Frontiers in immunology (23.10.2023)
Published in Frontiers in immunology (23.10.2023)
Get full text
Journal Article
Loading…
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T‐Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease
Ali, Sahra, Moreau, Alexandre, Melchiorri, Daniela, Camarero, Jorge, Josephson, Filip, Olimpier, Odoardo, Bergh, Jonas, Karres, Dominik, Tzogani, Kyriaki, Gisselbrecht, Christian, Pignatti, Francesco
Published in The oncologist (Dayton, Ohio) (01.04.2020)
Published in The oncologist (Dayton, Ohio) (01.04.2020)
Get full text
Journal Article
Loading…
TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer
Buelow, Ben, Dalvi, Pranjali, Dang, Kevin, Patel, Ashwin, Johal, Kiran, Pham, Duy, Panchal, Shailee, Liu, Yvonne, Fong, Lawrence, Sartor, A. Oliver, McKean, Meredith, Schellenberger, Ute, Iyer, Suhasini
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Loading…
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease
Ali, Sahra, Moreau, Alexandre, Melchiorri, Daniela, Camarero, Jorge, Josephson, Filip, Olimpier, Odoardo, Bergh, Jonas, Karres, Dominik, Tzogani, Kyriaki, Gisselbrecht, Christian, Pignatti, Francesco
Published in The oncologist (Dayton, Ohio) (01.04.2020)
Published in The oncologist (Dayton, Ohio) (01.04.2020)
Get full text
Journal Article
Loading…
Evaluating the Kinetics of Absolute Lymphocyte Counts Following Bispecific T-Cell Engager Therapy to Predict Clinical Outcomes in Relapsed/Refractory Multiple Myeloma
Bugarin-Estrada, Emmanuel, Monge, Jorge, Pearse, Roger, Niesvizky, Ruben, Mejia Saldarriaga, Mateo
Published in Blood (05.11.2024)
Published in Blood (05.11.2024)
Get full text
Journal Article
Loading…
Integrated Preclinical Data Analysis of ISB 2001 Enables Optimal Starting Dose Selection for a First-in-Class Trispecific T Cell Engager Phase1 Study in Multiple Myeloma
Drake, Adam, Pihlgren, Maria, Menon, Vinu, Pais, Daniela, Carretero-Iglesia, Laura, Berret, Jeremy, Hall, Olivia, Macoin, Julie, Gruber, Isabelle, Stainnack, Elodie, Estoppey, Carole, Dreyfus, Cyrille, Gudi, Girish, Matsuura, Tomomi, van der Graft, Piet H, Dyson, Michael, Konto, Cyril, Pacaud, Lida, Srivastava, Ankita, Zhukovsky, Eugene, Perro, Mario
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article